IN8bio
INAB
15 hedge funds and large institutions have $5.5M invested in IN8bio in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
7% more funds holding
Funds holding: 14 → 15 (+1)
0.05% more ownership
Funds ownership: 0.36% → 0.42% (+0.05%)
22% less capital invested
Capital invested by funds: $7.02M → $5.5M (-$1.51M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIG
Stonegate Investment Group
Birmingham,
Alabama
|
+$751K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
+$695K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$84.1K |
| 4 |
BlackRock
New York
|
+$34.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$507 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$575K |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$71.2K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$47K |
| 4 |
Morgan Stanley
New York
|
-$5.41K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Capital World Investors
Los Angeles,
California
| $1.88M | -$71.2K | -842 | -3% |
|
|
VC
2
Voss Capital
Houston,
Texas
| $1.14M | +$695K | +8,222 | +95% |
|
|
SIG
3
Stonegate Investment Group
Birmingham,
Alabama
| $602K | +$751K | +8,883 | New |
|
|
BRF
4
B. Riley Financial
Los Angeles,
California
| $582K | – | – | – |
|
|
NCM
5
Nantahala Capital Management
New Canaan,
Connecticut
| $359K | -$575K | -6,798 | -58% |
|
6
Vanguard Group
Malvern,
Pennsylvania
| $250K | -$2.2K | -26 | -0.7% |
|
|
SPC
7
Sigma Planning Corp
Ann Arbor,
Michigan
| $221K | – | – | – |
|
8
Ensign Peak Advisors
Salt Lake City,
Utah
| $170K | – | – | – |
|
|
BCM
9
Bridgeway Capital Management
Houston,
Texas
| $146K | – | – | – |
|
|
TSS
10
Two Sigma Securities
New York
| $67K | +$84.1K | +995 | New |
|
|
11
BlackRock
New York
| $65K | +$34.2K | +404 | +74% |
|
|
12
UBS Group
Zurich,
Switzerland
| $9K | +$507 | +6 | +5% |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $5K | -$3.38K | -40 | -35% |
|
|
14
Morgan Stanley
New York
| $2K | -$5.41K | -64 | -66% |
|
|
15
HighTower Advisors
Chicago,
Illinois
| – | -$47K | -472 | Closed |
|
INAB Hedge Fund Activity: Q2 2022 in Review
15 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q2 2022, worth a combined $5.5M — down 22% from $7.02M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new INAB positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Stonegate Investment Group, opening a new position worth an estimated $751K. The largest seller was Nantahala Capital Management, cutting an estimated $575K.
- 15 institutional investors held IN8bio (INAB) as of Q2 2022, up from 14 in Q1 2022.
- Funds reported $5.5M of IN8bio stock for Q2 2022, down 22% quarter-over-quarter.
- 2 funds opened new IN8bio positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest IN8bio buyer in Q2 2022 was Stonegate Investment Group, an estimated $751K added.
- The largest IN8bio seller in Q2 2022 was Nantahala Capital Management, an estimated $575K sold.
Based on aggregated 13F filings for Q2 2022.